Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Quality of Life Research
Published in: Quality of Life Research 6/2017

Open Access 01-06-2017

Long-term follow-up after active surveillance or curative treatment: quality-of-life outcomes of men with low-risk prostate cancer

Authors: Lionne D. F. Venderbos, Shafak Aluwini, Monique J. Roobol, Leonard P. Bokhorst, Eric H. G. M. Oomens, Chris H. Bangma, Ida J. Korfage

Published in: Quality of Life Research | Issue 6/2017

Login to get access

Abstract

Purpose

To compare long-term (4–10 years) quality of life (QoL) of men with low-risk prostate cancer (PCa) treated by different modalities and a reference group without PCa.

Methods

In this cross-sectional study, four groups were sent a one-time QoL-questionnaire; PCa patients (1) following the structured Prostate cancer Research International Active Surveillance protocol, (2) who underwent radical prostatectomy (RP) in the context of the European Randomized study of Screening for Prostate Cancer—section Rotterdam, (3) who underwent radiotherapy (RT) at an academic hospital in The Netherlands, and (4) an age-matched reference group of men without PCa. The QoL-questionnaire addressed prostate-specific health (EPIC), generic health (SF-12), and anxiety (STAI-6). Statistical significance (p ≤ 0.05) and clinical relevance (≥0.5 SD) of differences between groups were assessed.

Results

The AS, RP, RT, and reference group response rates amounted to 74% (122/165), 66% (70/106), 66% (221/335), and 75% (205/273), respectively. At a mean of 6.6 years of follow-up, active surveillance (AS)-men reported better urinary function [M = 93.0 (SD = 10.6) vs. 80.0 (SD = 19.1), p ≤ 0.001], less urinary incontinence [M = 90.0 (SD = 14.6) vs. 70.1 (SD = 28.8), p ≤ 0.001], and better sexual function [M = 40.9 (SD = 24.6) vs. 14.8 (17.7), p ≤ 0.001, clinically relevant] than RP-men. Compared to RT, AS-men reported better sexual function [M = 40.9 (SD = 24.6) vs. 25.8 (SD = 25.0), p = 0.069]. The four groups reported similarly low anxiety levels; the number of highly anxious men (STAI ≥ 44) ranged from 8 to 13%. For all QoL domains, men on AS and men without PCa reported very similar scores.

Conclusions

Prostate-specific function of AS-men was significantly better than that of RP-men. When comparing AS to RT, a borderline significant difference in sexual function was seen. Men who followed an AS strategy for a long-term period were not anxious and accepted it well, suggesting that AS may be a good treatment option for men with low-risk PCa.
Appendix
Available only for authorised users
Literature
1.
Sanda, M. G., Dunn, R. L., Michalski, J., Sandler, H. M., Northouse, L., Hembroff, L., Lin, X., Greenfield, T. K., Litwin, M. S., Saigal, C. S., Mahadevan, A., Klein, E., Kibel, A., Pisters, L. L., Kuban, D., Kaplan, I., Wood, D., Ciezki, J., Shah, N., & Wei, J. T. (2008). Quality of life and satisfaction with outcome among prostate-cancer survivors. The New England Journal of Medicine, 358(12), 1250–1261.CrossRefPubMed
2.
Cooperberg, M. R., & Carroll, P. R. (2015). Trends in management for patients with localized prostate cancer, 1990–2013. JAMA: The Journal of the American Medical Association, 314(1), 80–82.CrossRefPubMed
3.
Tran, K., Rahal, R., Fung, S., Louzado, C., Porter, G., Xu, J., Bryant, H., Collaboration with the System Performance Steering, C., & Technical Working, G. (2016). Patterns of care and treatment trends for Canadian men with localized low-risk prostate cancer: an analysis of provincial cancer registry data. Curr Oncol, 23(1), 56–59.CrossRefPubMedPubMedCentral
4.
Klotz, L., Vesprini, D., Sethukavalan, P., Jethava, V., Zhang, L., Jain, S., Yamamoto, T., Mamedov, A., & Loblaw, A. (2015). Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 33(3), 272–277.CrossRef
5.
Heidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., & Mottet, N. (2014). EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. European urology, 65(1), 124–137.CrossRefPubMed
6.
Thompson, I., Thrasher, J. B., Aus, G., Burnett, A. L., Canby-Hagino, E. D., Cookson, M. S., D’Amico, A. V., Dmochowski, R. R., Eton, D. T., Forman, J. D., Goldenberg, S. L., Hernandez, J., Higano, C. S., Kraus, S. R., Moul, J. W., Tangen, C. M., & Panel, A. U. A. P. C. C. G. U. (2007). Guideline for the management of clinically localized prostate cancer: 2007 update. The Journal of Urology, 177(6), 2106–2131.CrossRefPubMed
7.
Bruinsma, S. M., Bangma, C. H., Carroll, P. R., Leapman, M. S., Rannikko, A., Petrides, N., Weerakoon, M., Bokhorst, L. P., Roobol, M. J., & Movember, G. A. P. c (2016). Active surveillance for prostate cancer: a narrative review of clinical guidelines. Nature Reviews Urology, 13(3), 151–167.CrossRefPubMed
8.
Bellardita, L., Valdagni, R., van den Bergh, R., Randsdorp, H., Repetto, C., Venderbos, L. D., Lane, J. A., & Korfage, I. J. (2015). How does active surveillance for prostate cancer affect quality of life? A systematic review. European urology, 67(4), 637–645.CrossRefPubMed
9.
Watts, S., Leydon, G., Eyles, C., Moore, C. M., Richardson, A., Birch, B., Prescott, P., Powell, C., & Lewith, G. (2015). A quantitative analysis of the prevalence of clinical depression and anxiety in patients with prostate cancer undergoing active surveillance. BMJ Open, 5(5), e006674.CrossRefPubMedPubMedCentral
10.
Venderbos, L. D., van den Bergh, R. C., Roobol, M. J., Schroder, F. H., Essink-Bot, M. L., Bangma, C. H., Steyerberg, E. W., & Korfage, I. J. (2014). A longitudinal study on the impact of active surveillance for prostate cancer on anxiety and distress levels. Psychooncology.
11.
Marteau, T. M., Dormandy, E., & Michie, S. (2001). A measure of informed choice. Health Expectations: An International Journal of Public Participation in Health Care and Health Policy, 4(2), 99–108.CrossRef
12.
van den Bergh, R. C., Roemeling, S., Roobol, M. J., Roobol, W., Schroder, F. H., & Bangma, C. H. (2007). Prospective validation of active surveillance in prostate cancer: the PRIAS study. European urology, 52(6), 1560–1563.CrossRefPubMed
13.
Bokhorst, L. P., Alberts, A. R., Rannikko, A., Valdagni, R., Pickles, T., Kakehi, Y., Bangma, C. H., Roobol, M. J., & group, P. s. (2015). Compliance rates with the prostate cancer research international active surveillance (PRIAS) protocol and disease reclassification in noncompliers. Eur Urol.
14.
Schroder, F. H., Denis, L. J., Roobol, M., Nelen, V., Auvinen, A., Tammela, T., Villers, A., Rebillard, X., Ciatto, S., Zappa, M., Berenguer, A., Paez, A., Hugosson, J., Lodding, P., Recker, F., Kwiatkowski, M., Kirkels, W. J., & Erspc (2003). The story of the European Randomized Study of Screening for Prostate Cancer. BJU International, 92(Suppl 2), 1–13.CrossRefPubMed
15.
Wei, J. T., Dunn, R. L., Litwin, M. S., Sandler, H. M., & Sanda, M. G. (2000). Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology, 56(6), 899–905.CrossRefPubMed
16.
van Tol-Geerdink, J. J., Leer, J. W., van Oort, I. M., van Lin, E. J., Weijerman, P. C., Vergunst, H., Witjes, J. A., & Stalmeier, P. F. (2013). Quality of life after prostate cancer treatments in patients comparable at baseline. British Journal of Cancer, 108(9), 1784–1789.CrossRefPubMedPubMedCentral
17.
Ware, J., Jr., Kosinski, M., &amp, Keller, & S, D. (1996). A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Medical care, 34(3), 220–233.CrossRefPubMed
18.
19.
Marteau, T. M., & Bekker, H. (1992). The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). The British Journal of Clinical Psychology/The British Psychological Society, 31(Pt 3), 301–306.CrossRef
20.
Millar, K., Jelicic, M., Bonke, B., & Asbury, A. J. (1995). Assessment of preoperative anxiety: comparison of measures in patients awaiting surgery for breast cancer. British Journal of Anaesthesia, 74(2), 180–183.CrossRefPubMed
21.
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003). Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Medical care, 41(5), 582–592.PubMed
22.
Venderbos, L. D., van den Bergh, R. C., Roobol, M. J., Schroder, F. H., Essink-Bot, M. L., Bangma, C. H., Steyerberg, E. W., & Korfage, I. J. (2015). A longitudinal study on the impact of active surveillance for prostate cancer on anxiety and distress levels. Psycho-oncology, 24(3), 348–354.CrossRefPubMed
23.
Vasarainen, H., Lokman, U., Ruutu, M., Taari, K., & Rannikko, A. (2012). Prostate cancer active surveillance and health-related quality of life: results of the Finnish arm of the prospective trial. BJU International, 109(11), 1614–1619.CrossRefPubMed
24.
Simpkin, A. J., Tilling, K., Martin, R. M., Lane, J. A., Hamdy, F. C., Holmberg, L., Neal, D. E., Metcalfe, C., & Donovan, J. L. (2015). Systematic review and meta-analysis of factors determining change to radical treatment in active surveillance for localized prostate cancer. European urology, 67(6), 993–1005.CrossRefPubMed
25.
Donovan, J. L., Hamdy, F. C., Lane, J. A., Mason, M., Metcalfe, C., Walsh, E., Blazeby, J. M., Peters, T. J., Holding, P., Bonnington, S., Lennon, T., Bradshaw, L., Cooper, D., Herbert, P., Howson, J., Jones, A., Lyons, N., Salter, E., Thompson, P., Tidball, S., Blaikie, J., Gray, C., Bollina, P., Catto, J., Doble, A., Doherty, A., Gillatt, D., Kockelbergh, R., Kynaston, H., Paul, A., Powell, P., Prescott, S., Rosario, D. J., Rowe, E., Davis, M., Turner, E. L., Martin, R. M., Neal, D. E., & Protec, T. S. G. (2016). Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med.
26.
Sprangers, M. A., & Schwartz, C. E. (1999). Integrating response shift into health-related quality of life research: a theoretical model. Social Science and Medicine (1982), 48(11), 1507–1515.CrossRef
27.
Korfage, I. J., Hak, T., de Koning, H. J., & Essink-Bot, M. L. (2006). Patients’ perceptions of the side-effects of prostate cancer treatment–a qualitative interview study. Social Science and Medicine (1982), 63(4), 911–919.CrossRef
28.
Lepore S.J., & Eton D.T. (2000). Response shifts in prostate cancer patients: an evaluation of suppression and buffer models. In C. E. Schwartz and M. A. G. Sprangers (Eds.), Adaptation to changing health—response shift in quality-of-life research (pp.37–51). American Psychological Association; 2000. ISBN: 978-1-55798-710-5.
29.
Korfage, I. J., de Koning, H. J., & Essink-Bot, M. L. (2007). Response shift due to diagnosis and primary treatment of localized prostate cancer: a then-test and a vignette study. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 16(10), 1627–1634.CrossRef
30.
Taylor, S. E. (1983). Adjustment to threatening events—a theory of cognitive adaptation. American Psychologist, 38(11), 1161–1173.CrossRef
31.
Sinclair, V. G., & Blackburn, D. S. (2008). Adaptive coping with rheumatoid arthritis: the transforming nature of response shift. Chronic Illness, 4(3), 219–230.CrossRefPubMed
32.
Nicolosi, A., Laumann, E. O., Glasser, D. B., Moreira, E. D., Jr., Paik, A., Gingell, C., Global Study of Sexual, A., & Behaviors Investigators, G. (2004). Sexual behavior and sexual dysfunctions after age 40: the global study of sexual attitudes and behaviors. Urology, 64(5), 991–997.CrossRefPubMed
33.
Korfage, I. J., Roobol, M., de Koning, H. J., Kirkels, W. J., Schroder, F. H., & Essink-Bot, M. L. (2008). Does “normal” aging imply urinary, bowel, and erectile dysfunction? A general population survey. Urology, 72(1), 3–9.CrossRefPubMed
34.
Orom, H., Biddle, C., Underwood, W. 3rd, Nelson, C. J., & Homish, D. L. (2016). What is a “good” treatment decision? Decisional control, knowledge, treatment decision making, and quality of life in men with clinically localized prostate cancer. Medical Decision Making.
35.
Ruane-McAteer, E., O’Sullivan, J., Porter, S., Venderbos, L., & Prue, G. (2016). An exploration of men’s experiences of undergoing active surveillance for favourable-risk prostate cancer: A mixed methods study protocol. BMC Cancer, 16(1), 586.CrossRefPubMedPubMedCentral
36.
Otto, S. J., Schroder, F. H., & de Koning, H. J. (2004). Low all-cause mortality in the volunteer-based Rotterdam section of the European randomised study of screening for prostate cancer: self-selection bias? Journal of Medical Screening, 11(2), 89–92.CrossRefPubMed
37.
Nijs, H. G., Tordoir, D. M., Schuurman, J. H., Kirkels, W. J., & Schroder, F. H. (1997). Randomised trial of prostate cancer screening in The Netherlands: assessment of acceptance and motives for attendance. Journal of Medical Screening, 4(2), 102–106.CrossRefPubMed
Metadata
Title
Long-term follow-up after active surveillance or curative treatment: quality-of-life outcomes of men with low-risk prostate cancer
Authors
Lionne D. F. Venderbos
Shafak Aluwini
Monique J. Roobol
Leonard P. Bokhorst
Eric H. G. M. Oomens
Chris H. Bangma
Ida J. Korfage
Publication date
01-06-2017
Publisher
Springer International Publishing
Published in
Quality of Life Research / Issue 6/2017
Print ISSN: 0962-9343
Electronic ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-017-1507-7

Other articles of this Issue 6/2017

Quality of Life Research 6/2017 Go to the issue

OriginalPaper

How do Kenyan orphan girls experience less meaningful lives and how much does it matter for ‘health’?

OriginalPaper

The PROMIS fatigue item bank has good measurement properties in patients with fibromyalgia and severe fatigue

OriginalPaper

Quality of life and uncertainty in Crohn’s disease

OriginalPaper

Changes in health-related quality of life over a 1-year follow-up period in children with inflammatory bowel disease

OriginalPaper

Preliminary evidence on the uptake, use and benefits of the CONSORT-PRO extension

OriginalPaper

Patient versus general population health state valuations: a case study of non-specific low back pain